The Weight-Loss Pill Everyone Has Been Waiting For? MHRA Approves Eli Lilly's Foundayo

MHRA Approves Foundayo: How Eli Lilly's New Weight-Loss Pill Compares to Wegovy and Mounjaro

The UK's obesity treatment landscape has taken another major step forward.

Today, the Medicines and Healthcare products Regulatory Agency (MHRA) authorised Foundayo® (orforglipron), Eli Lilly's once-daily oral GLP-1 medicine for eligible adults with obesity, overweight with weight-related conditions, and type 2 diabetes.

The approval is significant because Foundayo offers patients an effective tablet alternative to injectable GLP-1 medicines, providing another option for people who may be reluctant to use weekly injections.

With the recent launch of Wegovy® Tablets, patients and healthcare professionals now have two oral GLP-1 medicines to consider alongside injectable treatments such as Wegovy and Mounjaro.

Here's everything you need to know.

Why Is Foundayo's MHRA Approval Important?

Over the past few years, GLP-1 medicines have transformed weight management by helping patients achieve clinically meaningful weight loss while improving blood sugar control.

Until recently, patients seeking the greatest benefits generally needed weekly injections.

Foundayo changes that.

As a once-daily tablet, it gives eligible patients another clinically proven treatment option without injections, making weight management therapy more accessible for many people.

For patients with needle anxiety or those looking for a treatment that fits more easily into daily life, today's approval represents an important milestone.

What Is Foundayo?

Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist developed by Eli Lilly.

It works by mimicking the body's natural GLP-1 hormone to:

• Reduce appetite
• Increase feelings of fullness
• Slow stomach emptying
• Improve blood glucose control

Alongside a reduced-calorie diet and increased physical activity, Foundayo is authorised for:

• Adults with obesity (BMI ≥30 kg/m²)
• Adults who are overweight (BMI ≥27 kg/m²) with at least one weight-related health condition
• Adults with inadequately controlled type 2 diabetes to improve glycaemic control

How Effective Is Foundayo?

Clinical studies have shown encouraging results.

Patients taking higher doses achieved around 12% average body weight loss, alongside significant improvements in HbA1c and blood glucose control.

Although injectable medicines such as Mounjaro continue to demonstrate the greatest average weight loss in clinical trials, Foundayo provides an effective oral alternative that many patients may find easier to use consistently.

Foundayo vs Wegovy Tablets vs Wegovy Injection vs Mounjaro

With several highly effective weight management medicines now available, choosing the right treatment can feel overwhelming.

Here's how they compare.

Which Treatment Might Be Right for You?

Each medicine has its own advantages.

Foundayo may suit patients who:

• Prefer tablets over injections
• Want a treatment with fewer administration restrictions
• Are looking for a convenient daily routine

Wegovy Tablets may appeal to patients who:

• Prefer oral treatment
• Are comfortable following fasting instructions before taking medication
• Wish to use an established semaglutide treatment

Wegovy Injection may be suitable for patients who:

• Prefer once-weekly dosing
• Have experience with injectable medicines
• Are eligible under current private prescribing criteria

Mounjaro may be preferred for patients who:

• Are seeking the greatest average weight loss demonstrated in clinical studies
• Are comfortable using a weekly injection
• Meet prescribing eligibility criteria

The best treatment depends on an individual's medical history, treatment goals, preferences and clinical assessment. Prescription weight-management medicines should only be started following advice from a qualified healthcare professional.

Can Patients Get Foundayo Now?

Although the MHRA has authorised Foundayo, this does not mean it is immediately available through the NHS.

Foundayo will be available privately very shortly. However, before NHS rollout, the medicine will undergo appraisal by the National Institute for Health and Care Excellence (NICE), which will assess its clinical and cost effectiveness.

Commercial launch plans and private availability are expected to follow regulatory processes.

Patients should always access prescription medicines through regulated healthcare providers.

Why This Matters

More than one in four adults in England lives with obesity, increasing the risk of conditions including:

• Type 2 diabetes
• Cardiovascular disease
• High blood pressure
• Sleep apnoea
• Certain cancers

The introduction of another effective treatment expands patient choice and supports more personalised weight-management pathways.

Importantly, medication is only one part of successful weight management. Long-term outcomes are best supported through lifestyle changes, nutritional guidance, regular physical activity and ongoing clinical review.

What This Means for Pharmulous Patients

At Pharmulous, we are committed to helping patients make informed decisions through evidence-based healthcare information and clinically led weight-management services.

As obesity treatments continue to evolve, we'll continue to monitor developments, including future NICE guidance and the availability of newly authorised medicines such as Foundayo.

If you're considering prescription weight-management treatment, our clinical team can help you understand which evidence-based options may be appropriate for your individual circumstances.

The Bottom Line

The MHRA's authorisation of Foundayo marks another important milestone in obesity treatment.

For the first time, patients in the UK have multiple oral GLP-1 options alongside established injectable therapies, allowing treatment decisions to be tailored to individual preferences and clinical needs.

Whether a patient chooses Foundayo, Wegovy Tablets, Wegovy Injection or Mounjaro, the most effective treatment is the one that is clinically appropriate, sustainable and supported by qualified healthcare professionals.

As new therapies become available, Pharmulous will continue to keep patients informed with the latest evidence, guidance and developments in weight management.

Frequently Asked Questions

What is Foundayo?

Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly for weight management and type 2 diabetes.

Is Foundayo available in the UK?

Yes. It has been authorised by the MHRA, but private availability will follow shortly. 

Is Foundayo better than Wegovy?

There is currently no direct head-to-head clinical trial comparing Foundayo with Wegovy. Both medicines are effective GLP-1 therapies, but they differ in their active ingredients, dosing requirements and clinical evidence.

Is Foundayo better than Mounjaro?

Mounjaro has demonstrated greater average weight loss in separate clinical trials. However, Foundayo offers the convenience of a once-daily tablet without injections. The right treatment depends on individual circumstances and should be discussed with a healthcare professional.

Can I get Foundayo from Pharmulous?

Availability will depend on future commercial launch plans and regulatory guidance. Pharmulous will provide updates as more information becomes available.

Sources

MHRA – UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
The Pharmacist – Eli Lilly's new weight-loss pill authorised by MHRA.
Novo Nordisk and MHRA information relating to oral Wegovy (semaglutide) tablets.